BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eosinophilic Esophagitis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Eosinophilic Esophagi
 tis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07112378-1356@assetmemo.bio
DTSTAMP:20261121T005002Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07112378)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Eosinophilic Esophagitis.\nStu
 dy: A Study of Dupilumab in Small Children With an Allergic Condition of t
 he Esophagus (Food Pipe): Eosinophilic Esophagitis\nEstimated primary comp
 letion: 19 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07112378
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
